Advanced LCNEC is often incorrectly related to SCLC, the latter of which is usually very chemosensitive and in which nivolumab gave disappointing results as second-line therapy (CheckMate-331), with low PD-L1 expression. This evidence concerns the gene CD274 and small cell lung carcinoma.